Not yet recruiting NCT07527130
C11 ER176 PET in Evaluating Neuroinflammation in Patients With Post-COVID Syndrome
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: C11 ER176 Tracer.
- Who it may be relevant to
- Registry conditions: COVID-19. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
The purpose of this research is to find out if Positron Emission Tomography (PET) imaging with an investigational drug called C-11 ER176 can help us learn more about Post-COVID Syndrome.
Interventions
- Drug C11 ER176 Tracer
C11 ER176 tracer will be administered by IV, followed by PET imaging of the brain to evaluate for neuroinflammation
Primary outcome measures
- Degree of Neuroinflammation [Time frame: Baseline reading only]
Eligibility criteria
Inclusion criteria
- Mayo Clinic patients with a previously confirmed infection with the novel SARS-CoV-2 virus who have been seen in the Post COVID Clinic through GIM Integrative Medicine \& Health Section or approval by MAGPIES research group.
- Be able to participate fully in all aspects of the study.
- Have understood and signed study informed consent.
Exclusion criteria
- Lacking the capacity to consent.
- Prisoners and institutionalized individuals.
- Reports being currently pregnant, lactating, or are of child-bearing potential or are likely to become pregnant during the LLLT treatment phase and are unwilling to use a reliable form of contraception.
o Acceptable forms include:
- Hormonal methods, such as birth control pills, patches, injections, vaginal ring, or implants
- Barrier methods (such as a condom or diaphragm) used with a spermicide (a foam, cream, or gel that kills sperm)
- Intrauterine device (IUD)
- Total hysterectomy or tubal ligation
- Abstinence (no sex).
- Those patients that have implants that would prevent them from having a PET Scan.
- Patients that have claustrophobia.
- Have a known history of any condition or factor judged by the investigator to preclude participation in the study or which might hinder adherence.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
United States · 1 center
- Mayo Clinic — Rochester
Identifiers
NCT: NCT07527130 · 23-003731